Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Part 1:
Part 2:
• Participants who completed the study treatment in Part 1 (Week 96 Visit), as per protocol.
Key Exclusion Criteria:
Part 1:
Part 2:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply"
Primary purpose
Allocation
Interventional model
Masking
142 participants in 2 patient groups
Loading...
Central trial contact
US Biogen Clinical Trial Center; Global Biogen Clinical Trial Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal